BrightEdge Fund
VC Fund
Atlanta, United States
BrightEdge Fund is a VC fund in Atlanta focused on Biotechnology and Health Care. BrightEdge is the American Cancer Society’s donor-funded, philanthropic impact fund. The fund is led by a board comprised of the Society’s leaders and a management team with expertise in investment and venture capital. BrightEdge operates under a charitable fund model that invests in for-profit companies developing novel cancer-focused therapiesand technologies. The fund relies on the expertise of the Society’s medical and science professionals to evaluate the mission value of its investments. The fund’s goal is to accelerate delivery of promising cancer-related solutions through capital investment, market awareness and a shared commitment to eradicate cancer.
- Total investments:
- 34
- Last investment:
- Lead investor:
- 9%
Last updated:
For AI agents: llms.txt
Industries BrightEdge Fund invests in
Stages BrightEdge Fund invests in
Countries BrightEdge Fund invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Seed
- $1.8M–$15M
- Series A
- $14M–$203M
- Series B
- $27M–$160M
Investment Focus
Industry
- Biotechnology 14 (41%)
- Health Care 13 (38%)
- Therapeutics 9 (26%)
- Medical 6 (18%)
- Health Diagnostics 4 (12%)
Stage
- Seed 6 (18%)
- Series A 6 (18%)
- Series B 6 (18%)
- Pre-Seed 2 (6%)
- Series C 2 (6%)
Country
- United States 17 (50%)
- Israel 1 (3%)
- United Kingdom 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Lucas de Breed
Director
|
Director | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Paradigm
|
Paradigm is rebuilding the clinical research ecosystem by developing a platform that allows all patients equitable access to trials while improving trial efficiency and lowering barriers to participation for healthcare providers. | $78M / Series B / Dec 04, 2025 | |
Alpheus Medical
|
Alpheus Medical provides a novel sonodynamic therapy platform targeting solid body cancers. Alpheus Medical also provides a non-invasive drug-device combination for outpatient treatment of recurrent glioblastoma multiforme (rGBM). | $52M / Series B / May 15, 2025 | |
Auron Therapeutics
|
Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancerto normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. | $27.3M / Series B / Feb 04, 2025 | |
Interius BioTherapeutics
|
Interius BioTherapeutics is a biopharmaceutical company that targets cancer. The company spun out the University of Pennsylvania and is targeting cancer. | $21.5M / Jan 01, 2025 | |
Nine Diagnostics
|
Functional Precision Medicine by Design. A faster path to the most effective treatment. | Pre-Seed / Oct 01, 2024 | |
Clasp Therapeutics
|
Clasp Therapeutics offers to reach of immuno-oncology with novel precision medicines that enable the immune system to identify and specifically destroy hard-to-treat tumors bearing common driver mutations, regardless of tumor type. | $150M / Series A / Mar 20, 2024 | |
Freenome
|
Freenome is a biotechnology company developing blood tests for early cancer detection to improve access to routine screening. | $254M / Feb 15, 2024 | |
Modifi Bio
|
Modifi Biosciences is a direct DNA modification developing novel cancer therapeutics. The company's strategy for combating cancer centers around modifying tumor DNA in a way that renders cancer cells irreparable while preserving the integrity of healthy cells. This unique approach empowers researchers to disrupt traditional oncology drugdevelopment methods. | $4.3M / Seed / Oct 16, 2023 | |
Thatch
|
Thatch helps businesses give great healthcare to their employees. | $5.6M / Seed / Feb 15, 2023 | |
|
Thatch
|
Thatch helps businesses give great healthcare to their employees. | $400K / Pre-Seed / Feb 15, 2023 | |
| See all 34 investments → | |||
Co-Investors
Polaris Partners
8 deals together
Google Ventures
6 deals together
S32
6 deals together
Bain Capital Life Sciences
5 deals together
F-Prime
5 deals together
RA Capital Management
5 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does BrightEdge Fund invest in?
BrightEdge Fund invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Seed and Series A stage. Most of the 34 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is BrightEdge Fund's check size?
BrightEdge Fund typically joins rounds of $1.8M–$15M at Seed, $14M–$203M at Series A and $27M–$160M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds BrightEdge Fund participates in.
How do I contact BrightEdge Fund?
Public channels for BrightEdge Fund include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at BrightEdge Fund?
The team at BrightEdge Fund includes Lucas de Breed (Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
